Every NR4A2 paper, in plain English

Epigenetic regulation of beta-endorphin synthesis in hypothalamic arcuate nucleus neurons modulates neuropathic pain in a rodent pain model.

Tao Y, Zhang Y, Jin X, Hua N, Liu H, Qi R, Huang Z, Sun Y, Jiang D, Snutch TP, Jiang X, Tao J

This study identifies a specific molecular pathway in rats where nerve injury triggers NR4A2 to increase miR-203a-3p, which reduces pain-relieving beta-endorphin and worsens neuropathic pain. While the same miRNA elevation appears in human trigeminal neuralgia patients, the findings are based on rodent models of pain rather than NR4A2-related developmental syndromes.

• NR4A2 upregulates miR-203a-3p in rat arcuate nucleus neurons after nerve injury.
• Increased miR-203a-3p reduces beta-endorphin synthesis, worsening neuropathic pain in rats.
• miR-203a-3p levels also rise in cerebrospinal fluid of human trigeminal neuralgia patients.
• The mechanism involves histone deacetylase 9 downregulation facilitating NR4A2 binding.
• Findings suggest potential therapeutic targets for neuropathic pain, not developmental disorders.

RNF125, transcriptionally regulated by NFATC2, alleviates osteoarthritis via inhibiting the Wnt/β-catenin signaling pathway through degrading TRIM14.

Lv R, Du L, Bai L

RNF125 protects joint cartilage in osteoarthritis by blocking a destructive signaling pathway, and its levels increase with exercise. This protein works by breaking down another protein, TRIM14, which otherwise promotes cartilage damage. The study shows that boosting RNF125 could be a new way to treat osteoarthritis.

• RNF125 protects cartilage in osteoarthritis
• Exercise increases RNF125 levels
• RNF125 degrades TRIM14 to block cartilage damage
• RNF125 stops a harmful Wnt signaling pathway
• NR4A2 supports RNF125’s protective role

Exploring Fatty Acid Mimetics as NR4A Ligands.

Stiller T, Merk D

Researchers identify new chemical compounds that activate NR4A transcription factors with high potency. These fatty acid mimetics serve as precise tools for studying NR4A biology in laboratory settings. The study does not test these compounds in humans or animal models of disease.

• Eleven new scaffolds activate or inhibit NR4A receptors in lab tests.
• Optimized compounds show submicromolar potency and strong binding affinity.
• Fatty acid mimetics offer a new avenue for NR4A modulation research.
• No clinical data, patient outcomes, or therapeutic efficacy are reported.

Prognostic Factors for Restenosis of Superficial Femoral Artery after Endovascular Treatment.

Boc V, Kozak M, Eržen B, Božič Mijovski M, Boc A, Blinc A

This study found that poor blood flow below the knee, complex artery blockages, and certain blood clotting patterns increase the risk of artery narrowing after treatment for leg artery disease. These factors help predict which patients are more likely to need repeat procedures.

• Poor blood flow below the knee raises restenosis risk
• Complex blockages increase likelihood of re-narrowing
• Abnormal clotting patterns predict treatment failure
• Restenosis often happens without symptoms
• Treating both leg and lower leg arteries may help

Expression of selected nuclear receptors in human epithelial ovarian cell line Caov3 exposed to bisphenol derivatives.

Mlynarcikova AB, Macejova D, Scsukova S

This study found that high doses of bisphenol A and its analogs can alter the mRNA levels of certain nuclear receptors in human ovarian cells, but lower doses had no effect. The changes were seen only at very high concentrations, not at levels typically found in human exposure.

• High doses of BPA and BPAF changed nuclear receptor genes
• No effects at low, realistic exposure levels
• NURR1 and other receptors were affected at 100 µM
• Cell viability was only impaired at the highest BPAF dose
• Findings suggest limited risk at typical exposure levels

Single-nuclei RNA sequencing uncovers heterogenous transcriptional signatures in Parkinson's disease associated with nuclear receptor-related factor 1 defect.

Kambey PA, Liu WY, Wu J, Bosco B, Nadeem I, Kanwore K, Gao DS

Nurr1 deficiency in mouse brains triggers an immune response that destroys dopaminergic neurons, suggesting that targeting this pathway could treat Parkinson's disease. This study identifies specific genes involved in this process but does not provide evidence for treatments or outcomes in humans with NR4A2-related syndromes.

• Nurr1 loss increases immune system gene expression in mouse brain cells.
• The study uses a mouse model, not human patients or clinical data.
• Findings suggest potential drug targets for Parkinson's disease pathology.
• No information is provided about NR4A2 variants or human phenotypes.

Bioinformatics led discovery of biomarkers related to immune infiltration in diabetes nephropathy.

Wang S, Chen S, Gao Y, Zhou H

This study identifies NR4A2 as one of seven genes associated with immune infiltration in diabetic kidney disease using bioinformatics analysis. The research focuses on understanding inflammation mechanisms in diabetes rather than NR4A2-related neurological syndromes.

• NR4A2 appears as a biomarker for immune infiltration in diabetic nephropathy.
• The study uses bioinformatics to analyze gene expression in kidney disease.
• No clinical trials or treatments for NR4A2 syndrome are mentioned.
• Findings relate to diabetes complications, not neurological development.

A role of NR4A2 in Graves' disease: regulation of Th17/Treg.

Zhao S, Wang X, Huang F, Zhou Y, Meng D, Zhao D, Wang J, Zhang H, Wu L, Zhang Y, Zhao L, Zhang L, Song Y, Wang Q

This study finds that low levels of NR4A2 in immune cells contribute to Graves' disease by reducing regulatory T cells, but it does not address the neurological or developmental aspects of NR4A2 syndrome. The findings are specific to thyroid autoimmunity and do not provide insight into the child's condition. There is no direct relevance to treatment or understanding of NR4A2-related neurodevelopmental disorders.

• NR4A2 levels are low in T cells from Graves' disease patients.
• Low NR4A2 reduces regulatory T cell differentiation and IL-10 production.
• NR4A2 does not significantly affect Th17 cell differentiation.
• The study focuses on thyroid autoimmunity, not neurological function.
• No connection to dopaminergic pathways or neurodevelopmental phenotypes is established.

Acute Effects of Single Versus Combined Inhaled β2-Agonists Salbutamol and Formoterol on Time Trial Performance, Lung Function, Metabolic and Endocrine Variables.

Bizjak DA, Nussbaumer D, Winkert K, Treff G, Takabajashi K, Mentz L, Schober F, Buhl JL, John L, Dreyhaupt J, Steeb L, Harps LC, Parr MK, Diel P, Zügel M, Steinacker JM

Inhaled salbutamol, formoterol, or their combination did not improve endurance performance in healthy athletes, despite changes in lung function, heart function, and metabolic markers like NR4A2. The study found no performance benefit at permitted doses, though molecular and hormonal effects were observed, especially in women.

• No performance improvement from inhaled β2-agonists
• NR4A2 gene expression changed with treatment
• Heart and lung function altered without performance impact
• Higher drug levels in female athletes
• No evidence of doping benefit at legal doses

Ferulic Acid reduces amyloid beta mediated neuroinflammation through modulation of Nurr1 expression in microglial cells.

Moghimi-Khorasgani A, Homayouni Moghadam F, Nasr-Esfahani MH

Ferulic acid reduces inflammation in mouse microglial cells by increasing Nurr1 levels and shifting the cells to a non-inflammatory state. This effect occurs in response to amyloid beta stress, suggesting a potential mechanism for neuroprotection. The study provides no evidence of human application or clinical benefit.

• Ferulic acid increases Nurr1 expression in mouse microglial cells.
• Treatment reduces inflammatory markers IL-1β and increases anti-inflammatory IL-10.
• Cells shift from a reactive to a non-inflammatory morphology under stress.
• Study uses only mouse cell cultures, not human subjects or animals.
• No clinical data or relevance to NR4A2 syndrome treatment is provided.

Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.

Park JS, Choe K, Lee HJ, Park TJ, Kim MO

Osmotin protects dopaminergic neurons and improves motor and cognitive symptoms in mouse models of Parkinson's disease by upregulating Nurr1 and reducing inflammation. This preclinical study demonstrates that osmotin rescues pathology associated with alpha-synuclein accumulation through specific signaling pathways.

• Osmotin upregulates Nurr1, a transcription factor critical for dopaminergic neuron survival.
• The treatment reduces neuronal death and neuroinflammation in Parkinson's disease mouse models.
• Osmotin improves motor dysfunction and cognitive deficits caused by alpha-synuclein toxicity.
• This is animal research only; no human clinical data or trials are reported.

Mechanisms of NURR1 Regulation: Consequences for Its Biological Activity and Involvement in Pathology.

García-Yagüe ÁJ, Cuadrado A

This review summarizes how NURR1 protein activity is controlled through chemical modifications and interactions with other proteins, which influence its stability and function in brain development. It outlines the known regulatory mechanisms of NURR1 and briefly discusses its potential role in various pathological conditions.

• NURR1 regulates dopaminergic neuron development and stress responses in the developing brain.
• Phosphorylation and SUMOylation are key chemical modifications that control NURR1 activity.
• Protein interactions and cellular location also influence NURR1's transcriptional function.
• The paper reviews current knowledge on NURR1 regulation and its link to disease.

The spatiotemporal dynamics of spatially variable genes in developing mouse brain revealed by a novel computational scheme.

Hong Y, Song K, Zhang Z, Deng Y, Zhang X, Zhao J, Jiang J, Zhang Q, Guo C, Peng C

This study develops a computational tool to map gene activity in developing mouse brains and confirms that Nr4a2 expression patterns help distinguish between the neocortex and hippocampus. The research provides no clinical data, human trials, or therapeutic insights for NR4A2-related syndromes.

• The paper uses a new computational method to analyze spatial gene expression in mouse brains.
• It confirms Nr4a2 helps separate neocortex and hippocampus regions during development.
• The study relies entirely on mouse models and public datasets, with no human participants.
• No treatments, clinical outcomes, or direct relevance to NR4A2 syndrome are discussed.

Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2.

Li B, Yang Z, Mao F, Gong W, Su Q, Yang J, Liu B, Song Y, Jin J, Lu Y

This study identifies Nr4a2 as a driver of liver disease progression in NASH, showing that suppressing this gene protects mice from fatty liver inflammation and fibrosis. While the findings confirm Nr4a2's role in hepatocytes, they do not provide evidence for treating NR4A2-related neurological syndromes.

• Nr4a2 promotes liver fat accumulation and inflammation in mouse models of NASH.
• Knocking out Nr4a2 in the liver protects mice from diet-induced liver damage.
• Nr4a2 levels are higher in human NASH patients, correlating with disease severity.
• The research focuses on liver pathology, not neurological or dopaminergic functions.

Smoke and Spike: Benzo[a]pyrene Enhances SARS-CoV-2 Infection by Boosting NR4A2-Induced ACE2 and TMPRSS2 Expression.

Liu W, Zhao Y, Fan J, Shen J, Tang H, Tang W, Wu D, Huang W, Ding Y, Qiao P, Lin J, Li Z, Li Q, Cui Q, Liu Y, Chen Y, Pu R, Han X, Yin J, Tan X, Cao G

Cigarette smoke contains benzo[a]pyrene, which increases the risk of SARS-CoV-2 infection by boosting NR4A2, a gene that turns on ACE2 and TMPRSS2—two proteins the virus uses to enter cells. This effect happens even in people without common genetic variants in these genes and is seen in human lung cells and animal models. Reducing NR4A2 or using interferon-λ can block this process and lower infection risk.

• Benzo[a]pyrene in smoke boosts NR4A2, increasing viral entry proteins
• NR4A2 drives ACE2 and TMPRSS2 expression independently of genetic variants
• NR4A2 reduction or interferon-λ blocks infection in human and animal models
• Aging increases NR4A2 and its target genes, raising infection risk
• This explains why smoking worsens COVID-19 and suggests protective strategies

Origin and development of the claustrum in rhesus macaque.

Li H, Duque A, Rakic P

This study maps the developmental timeline and cellular origins of the claustrum in rhesus macaques, identifying when specific neurons form and which molecular markers they express. It establishes that the claustrum develops as an independent pallial region with a distinct core-shell structure driven by two waves of neurogenesis.

• Claustrum neurons generate between embryonic days E48 and E55 in rhesus macaques.
• Early claustrum cells express NR4A2, SATB2, and SOX5 but lack TBR1 expression.
• Two neurogenesis waves create a core-shell architecture potentially supporting higher cognition.
• Parvalbumin-positive interneurons dominate the fetal claustrum and mature independently of the neocortex.
• The claustrum is an independent pallial region, not a continuation of insular subplate neurons.

Sodium Butyrate Ameliorates Deoxynivalenol-Induced Oxidative Stress and Inflammation in the Porcine Liver via NR4A2-Mediated Histone Acetylation.

Zong Q, Li K, Qu H, Hu P, Xu C, Wang H, Wu S, Wang S, Liu HY, Cai D, Bao W

Sodium butyrate reduces liver inflammation and oxidative stress in piglets exposed to a common food toxin by regulating the NR4A2 protein. This study demonstrates that NR4A2 plays a role in controlling inflammatory gene expression through histone modification mechanisms.

• Sodium butyrate reverses liver damage caused by deoxynivalenol exposure in piglets.
• NR4A2 activation is linked to increased oxidative stress and inflammation pathways.
• Treatment reduces NR4A2 binding to inflammatory gene promoters via histone acetylation.
• Findings are based on a porcine animal model of toxin-induced injury.

Insulin enhances contextual fear memory independently of its effect in increasing plasma adrenaline.

Oliveira A, Seixas R, Pereira F, Azevedo M, Martinho R, Serrão P, Moreira-Rodrigues M

Insulin improves fear memory in mice through central brain changes that do not require adrenaline or blood sugar shifts. This study measures Nr4a2 gene activity in the hippocampus during this process, but it does not test treatments for NR4A2-related syndromes.

• Insulin enhances fear memory even without adrenaline present.
• The effect relies on central brain changes, not peripheral hormones.
• Nr4a2 expression increases in the hippocampus after insulin treatment.
• This is a basic science study using mouse models only.

Alternative activation.

Young K, Fanning S

Researchers discover a new mechanism by which ligands control the transcriptional activity of Nurr1, an orphan receptor linked to neurodegenerative diseases. This finding expands the understanding of how this specific protein regulates gene expression.

• The study identifies an alternative activation pathway for the Nurr1 receptor.
• Ligands control Nurr1's transcriptional activity through a newly revealed mechanism.
• Nurr1 is a known regulator implicated in neurodegenerative conditions.

DNA methylation clocks for clawed frogs reveal evolutionary conservation of epigenetic aging.

Zoller JA, Parasyraki E, Lu AT, Haghani A, Niehrs C, Horvath S

This study establishes that DNA methylation patterns associated with aging are evolutionarily conserved between frogs and humans. It identifies the NR4A2 gene as one of the neural-developmental genes where these age-related epigenetic changes occur.

• Epigenetic clocks developed in frogs also apply to humans, confirming evolutionary conservation of aging signatures.
• NR4A2 is identified among genes with conserved, age-related DNA methylation changes linked to neural processes.
• The findings support using Xenopus frogs as a model organism for studying human aging mechanisms.

De Novo Design of Nurr1 Agonists via Fragment-Augmented Generative Deep Learning in Low-Data Regime.

Ballarotto M, Willems S, Stiller T, Nawa F, Marschner JA, Grisoni F, Merk D

Researchers used artificial intelligence to design a new molecule that activates the Nurr1 protein, which is encoded by the NR4A2 gene. This novel compound shows strong binding affinity and potency in laboratory tests, offering a potential starting point for future drug development.

• AI designed a new Nurr1 agonist using only one known active molecule as a template.
• The new compound binds tightly to Nurr1 and shows nanomolar potency in lab assays.
• This work demonstrates that AI can create drugs for targets with very little existing data.
• The molecule serves as an early chemical tool for studying Nurr1 function.

Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA.

Jiang L, Liu X, Liang X, Dai S, Wei H, Guo M, Chen Z, Xiao D, Chen Y

This study reveals how the FXR/RXR protein complex binds to specific DNA sequences, but it does not involve NR4A2 or relate to NR4A2-related syndrome. The findings are about a different nuclear receptor system and do not provide insights into NR4A2 biology or potential treatments.

• FXR/RXR binds DNA through a specific site called IR1
• NR4A2 does not form heterodimers with RXR at IR1 sites
• The study focuses on FXR, not NR4A2 or related disorders
• No direct relevance to NR4A2-related syndrome or treatment

Latroeggtoxin-VI protects nerve cells and prevents depression by inhibiting NF-κB signaling pathway activation and excessive inflammation.

Wang H, Zhai Y, Lei Z, Chen S, Sun M, Yin P, Duan Z, Wang X

A spider venom protein reduces inflammation and protects nerve cells in mouse models of depression. The study shows this compound prevents the loss of Nurr1, a protein related to NR4A2, by blocking inflammatory signaling pathways.

• The study uses mouse models and cell lines, not human participants.
• It tests a spider venom protein, not a current or planned clinical therapy.
• Nurr1 is mentioned only as a marker affected by inflammation in this context.

Clorfl86/RHEX Is a Negative Regulator of SCF/KIT Signaling in Human Skin Mast Cells.

Franke K, Bal G, Li Z, Zuberbier T, Babina M

RHEX is a protein that turns down the activity of KIT signaling in human skin mast cells, which helps control cell survival and gene activation. Reducing RHEX leads to stronger KIT signaling and increased expression of genes like NR4A2, which are involved in immune responses.

• RHEX acts as a brake on KIT signaling in mast cells
• Lower RHEX levels boost cell survival and gene activation
• RHEX reduction increases NR4A2, JUNB, and EGR1 expression
• RHEX is highly specific to mast cells, making it a potential marker
• This pathway may influence immune and inflammatory responses

Molecular basis of ligand-dependent Nurr1-RXRα activation.

Yu X, Shang J, Kojetin DJ

This study reveals that certain drugs activate the NR4A2 protein by breaking its bond with another protein, RXRα, rather than by directly stimulating it. This mechanism suggests a new way to potentially treat neurodegenerative conditions by targeting this specific protein interaction.

• RXRα ligands activate NR4A2 by weakening its bond with RXRα.
• This releases active NR4A2 monomers from a repressive complex.
• The mechanism differs from classical nuclear receptor activation models.
• Findings provide a blueprint for small molecule drug design.

Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.

Kambey PA, Liu WY, Wu J, Tang C, Buberwa W, Saro A, Nyalali AMK, Gao D

Blocking a protein called Amphiregulin reduces abnormal movements caused by long-term levodopa treatment in a mouse model of Parkinson's disease, suggesting a potential new treatment target for drug-induced dyskinesia.

• Amphiregulin levels rise in mice with levodopa-induced dyskinesia
• Reducing Amphiregulin lessens abnormal movements and key dyskinesia markers
• Blocking the ERK pathway also lowers Amphiregulin, linking it to known dyskinesia mechanisms
• Amphiregulin may be a promising new target for treating dyskinesia

Want of Wnt in Parkinson's disease: Could sFRP disrupt interplay between Nurr1 and Wnt signaling?

Gamit N, Dharmarajan A, Sethi G, Warrier S

This review outlines how the Wnt signaling pathway supports midbrain dopaminergic neurons by activating Nurr1 and suppressing alpha-synuclein, a protein linked to Parkinson's disease. It proposes that blocking Wnt antagonists like sFRPs could potentially restore this protective mechanism.

• Nurr1 maintains dopaminergic neurons and suppresses alpha-synuclein overexpression.
• Wnt signaling activates Nurr1 to protect against Parkinson's disease pathology.
• sFRP proteins inhibit Wnt signaling, potentially disrupting this protective pathway.
• The paper hypothesizes that targeting sFRPs may offer a treatment strategy for Parkinson's.

Aberrant somatic calcium channel function in cNurr1 and LRRK2-G2019S mice.

Skiteva O, Yao N, Mantas I, Zhang X, Perlmann T, Svenningsson P, Chergui K

This study finds that removing the Nurr1 gene in adult mice alters calcium channel function in dopamine neurons, but it does not provide evidence for treating children with NR4A2-related syndromes. The research focuses on molecular mechanisms in mouse models of Parkinson's disease rather than developmental outcomes or therapies relevant to your child.

• The study uses adult mice with Nurr1 deletion, unlike the developmental context of NR4A2 syndrome.
• It investigates calcium channel changes in dopamine neurons, not clinical symptoms or treatment responses.
• Findings are preclinical and do not translate to human pediatric care or genetic counseling.

Temporal origin of mouse claustrum and development of its cortical projections.

Hoerder-Suabedissen A, Ocana-Santero G, Draper TH, Scott SA, Kimani JG, Shelton AM, Butt SJB, Molnár Z, Packer AM

This study maps the development of the mouse claustrum, showing that its neurons are born around embryonic day 12.5 and form connections with the cortex at different times—some early, others later. The claustrum's unique wiring pattern emerges gradually, with key connections forming by postnatal day 10.

• Claustrum neurons are born around embryonic day 12.5
• Connectivity with the cortex develops at different rates
• Some connections form by postnatal day 10, others later
• Nurr1+ cells mark the core of the claustrum from birth
• The claustrum's structure becomes visible by postnatal day 15

Protective effect of Nr4a2 (Nurr1) against LPS-induced depressive-like behaviors via regulating activity of microglia and CamkII neurons in anterior cingulate cortex.

He Y, Wang Y, Yu H, Tian Y, Chen X, Chen C, Ren Y, Chen Z, Ren Y, Gong X, Cheng K, Liu X, Zhong L, Guo Y, Xie P

Activating the Nr4a2 protein in mouse brains reduces depressive-like behaviors caused by inflammation. This effect occurs by protecting neurons and calming immune cells in a specific brain region involved in mood regulation.

• Nr4a2 activation reverses depression-like symptoms in inflamed mice.
• The drug amodiaquine mimics Nr4a2 activity and improves behavior.
• Nr4a2 protects neuron structure and reduces microglia inflammation.
• This study uses mouse models, not human patients.

A potential protective role of the nuclear receptor-related factor 1 (Nurr1) in multiple sclerosis motor cortex: a neuropathological study.

Pansieri J, Pisa M, Yates RL, Esiri MM, DeLuca GC

This study finds that the protein Nurr1 is more abundant in the motor cortex of people with multiple sclerosis and correlates with better neuronal survival and lower levels of inflammatory immune cells. These observations suggest Nurr1 may help protect brain tissue from damage during inflammation, although this finding comes from post-mortem analysis of a different disease.

• Nurr1 levels are higher in the motor cortex of multiple sclerosis patients than in controls.
• Higher Nurr1 expression links to greater neuronal density and fewer inflammatory CD8+ cells.
• The study analyzes human brain tissue from post-mortem multiple sclerosis cases.
• Findings suggest a potential protective role for Nurr1 against neurodegeneration and inflammation.
• This research focuses on multiple sclerosis pathology, not NR4A2-related developmental syndromes.

Activity-Dependent Nr4a2 Induction Modulates Synaptic Expression of AMPA Receptors and Plasticity via a Ca2+/CRTC1/CREB Pathway.

Català-Solsona J, Lituma PJ, Lutzu S, Siedlecki-Wullich D, Fábregas-Ordoñez C, Miñano-Molina AJ, Saura CA, Castillo PE, Rodriguez-Álvarez J

This study identifies a molecular pathway in mouse neurons where Nr4a2 activation increases synaptic strength and plasticity by boosting BDNF and AMPA receptors. The findings suggest that activating Nr4a2 could theoretically help treat brain disorders linked to faulty synaptic connections, though this has not been tested in humans.

• Researchers used mouse hippocampal neurons and acute slices for all experiments.
• Nr4a2 activation increases BDNF production and AMPA receptor expression at synapses.
• The mechanism involves a calcium-dependent signaling pathway linking activity to gene expression.
• No human data, clinical trials, or patient outcomes are reported in this paper.

Correction for Zhao et al., Integrative analysis reveals structural basis for transcription activation of Nurr1 and Nurr1-RXRα heterodimer.

This correction clarifies the structural details of how the Nurr1 protein and its partner RXRα bind together to activate gene transcription. It does not introduce new biological findings or clinical data.

• The paper corrects structural analysis of the Nurr1-RXRα heterodimer complex.
• It explains the molecular basis for transcription activation by this protein pair.
• No human patient data, animal models, or treatment outcomes are reported.
• This is a technical correction to previous molecular biology research.

The Influence of Prenatal Exposure to Methamphetamine on the Development of Dopaminergic Neurons in the Ventral Midbrain.

Alsanie WF, Abdelrahman S, Felimban RI, Alkhatabi HA, Gaber A, Alosimi EA, Alhomrani M, Habeeballah H, Hauser CAE, S Alamri A, Althobaiti A, Alsharif A, Alzahrani AS, Al-Ghamdi MS, Raafat BM, Alswat KA, Althobaiti YS, Asiri YA

Prenatal methamphetamine exposure reduces the expression of key genes required for dopaminergic neuron development in mice, suggesting potential harm to fetal brain formation. The study finds that while cell survival remains intact, critical genetic pathways for neuron differentiation are disrupted by drug exposure.

• Methamphetamine downregulates genes essential for dopaminergic neuron differentiation in mouse embryos.
• Cell viability and morphology remain unaffected, but ATP release decreases slightly.
• Nurr1 expression remains stable despite the reduction in other neurogenesis-related genes.
• Findings suggest caution regarding methamphetamine use during pregnancy due to developmental risks.

Transcriptomic Analysis Reveals mRNA and Alternative Splicing Events in Ovine Skeletal Muscle Satellite Cells during Proliferation and Differentiation.

Chen Q, Huang C, Su Y, Zhao Q, Pu Y, He X, Jiang L, Ma Y, Zhao Q, Ye S

This study maps gene activity in sheep muscle stem cells to understand how they grow and repair tissue. It identifies NR4A2 as one of several transcription factors that likely interact with other proteins to regulate this process.

• Researchers analyzed RNA from sheep muscle stem cells during growth phases.
• They identified thousands of genes that change expression or splicing patterns.
• Signaling pathways like MAPK and Wnt are active in these cells.
• NR4A2 appears alongside MEF2C, suggesting they work together in muscle development.